Search All News
Source:Department of Pediatrics
A team of Columbia physician-scientists have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier to better treat pediatric brain tumors.
Tannishtha Reya, PhD, is establishing the new Irving Cancer Drug Discovery Program, devoted to helping faculty accelerate research discoveries in their labs to the clinic.
Exciting new clinical investigations, including results of the ALPINE study, show promising, more effective treatment for patients with CLL.
Peter encourages others to look into clinical trials and not lose hope.
Source:CUIMC NewsroomNovember 10, 2022
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
- November 3, 2022
Results of a multi-center study, co-led by Dr. Richard Carvajal, demonstrates a promising new immunotherapy for patients with rare uveal melanoma.
- October 25, 2022
Melissa Accordino, MD, tackles solutions to long-term side effects, like peripheral neuropathy, that some breast cancer survivors experience after overcoming the disease.
- September 26, 2022
During First Lady Jill Biden's Columbia Sept. 21 visit, she singles out patient, Mario Sambula and his special connection with clinical trials nurse navigator, Brianne Bodin.
Source:CUIMC NewsroomSeptember 23, 2022
As part of the Biden Administration's Cancer Moonshot initiative, First Lady Jill Biden and Queen Letizia of Spain visited Columbia University's cancer center on Sept. 21.
- September 21, 2022
First Lady Jill Biden and Queen Letizia of Spain underscore Columbia Cancer's work in addressing health inequities, improving diversity in clinical trials and advancing critical cancer research.
- July 18, 2022
Under her directorship, Dr. Karen Antman led the expansion of the Cancer Center's clinical arm, infrastructure and multi-disciplinary care.
Source:NRG OncologyJune 28, 2022
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
Source:SWOG Cancer Research NetworkMay 27, 2022
A study, led by Dr. Dawn Hershman, tested whether standing orders embedded in electronic medical records systems could improve prescribing practice for CSFs and lower incidence of febrile neutropenia.
- March 28, 2022
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.